Journal Article

Treatment of Older Patients with Mantle-Cell Lymphoma

Walewski, J, Forstpointner, R, Thieblemont, C, Hallek, M, André, M, Szymczyk, M, Di Raimondo, F, Klapper, W, Vehling-Kaiser, U, Hermine, O, Macro, M, Ribrag, V, Kluin-Nelemans, H.C, Tilly, H, Kremers, S, Dreyling, M.H, Zijlstra, J.M, Lepeu, G, Uppenkamp, M, Bouabdallah, R, Feugier, P, Pfreundschuh, M, Kanz, L, Sanhes, L, Doorduijn, J.K, Geisler, C.H, Lugtenburg, P.J, Unterhalt, M, Hoster, E, Stilgenbauer, S, Coiffier, B, Trneny, M, Procházka, V, Hiddemann, W

2012

Overview

This international prospective study showed that maintenance therapy with rituximab was more effective than interferon alfa in prolonging the duration of remission and extending survival in older patients with mantle-cell lymphoma. Patients with mantle-cell lymphoma typically present with extensive disease and involvement of multiple lymph nodes as well as the spleen, bone marrow, blood, and gastrointestinal tract. The median age at diagnosis is about 65 years. 1 , 2 Standard therapy for these patients consists of chemotherapy (e.g., the CHOP regimen, consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone) combined with the anti-CD20 monoclonal antibody rituximab (e.g., R-CHOP). 2 – 4 Only a minority of patients have a complete remission, and relapse or progression usually occurs within 2 to 3 years, resulting in an overall survival of less than 5 years. To improve this grim prognosis, . . .

• Publisher: Massachusetts Medical Society
• Subject: Age / Aged / Aged, 80 and over / Antibodies, Monoclonal, Murine-Derived - administration & dosage / Antibodies, Monoclonal, Murine-Derived - adverse effects / Antibodies, Monoclonal, Murine-Derived - therapeutic use / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Biological and medical sciences / Clinical trials / Computer centers / Cyclophosphamide / Cyclophosphamide - administration & dosage / Cyclophosphamide - adverse effects / Cyclophosphamide - therapeutic use / Doxorubicin / Doxorubicin - adverse effects / Doxorubicin - therapeutic use / Drug therapy / Female / Fludarabine / General aspects / Hematologic and hematopoietic diseases / Humans / Induction Chemotherapy / Intention to Treat Analysis / Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis / Lymphoma / Lymphoma, Mantle-Cell - drug therapy / Lymphoma, Mantle-Cell - mortality / Maintenance Chemotherapy / Male / Medical sciences / Middle Aged / Monoclonal antibodies / Motivation / Older people / Patients / Prednisone / Prednisone - adverse effects / Prednisone - therapeutic use / Prospective Studies / Remission / Remission Induction / Rituximab / Survival Rate / Targeted cancer therapy / Vidarabine - administration & dosage / Vidarabine - analogs & derivatives / Vincristine / Vincristine - adverse effects / Vincristine - therapeutic use / α-Interferon